Up-to-date List of Vyvanse Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Vyvanse Medical Research Studies

RankStatusStudy
1 Recruiting Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Condition: ADHD
Intervention: Drug: Lisdexamphetamine
Outcome Measures: fMRI;   BRIEF-A;   ASRS - expanded;   WRAADS;   ADHD-RS;   CGI-I/CGI-S
2 Recruiting Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
Condition: Major Depressive Disorder
Intervention: Drug: Lisdexamfetamine Dimesylate 20-50 mg
Outcome Measure: Change in the dysphoric apathy/retardation sub-factor of Montgomery-Asberg Depression Rating Scale (MADRS).
3 Recruiting Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
Condition: Cocaine Dependence
Intervention: Drug: Lisdexamfetamine
Outcome Measures: the maximum total lisdexamfetamine dose achieved;   Change in Cocaine use;   Change in Cocaine craving
4 Recruiting Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Condition: Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders
Interventions: Drug: Lisdexamfetamine Dimesylate;   Drug: placebo
Outcome Measures: ADHD Rating Scale;   Clinical Global Impression - Improvement Scale (CGI-I);   Yale Global Tic Severity Scale (YGTSS);   the Overall Anxiety Severity and Impairment Scale (OASIS);   The Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S);   Barkley Adult ADHD Rating Scale--IV(BAARS-IV);   Revised Padua Inventory;   The Panic and Agoraphobia Scale (PAS);   Quick Inventory of Depressive Symptoms (QID-SR-16);   The Sheehan Disability Scale (SDS);   GAD-7;   Social Phobia Inventory (SPIN);   The Life Events Questionnaire (LEQ);   The Pittsburgh Sleep Quality Index (PSQI);   Clinical Global Impression - Severity (CGI-S)
5 Recruiting Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Condition: Severe Mood Dysregulation
Interventions: Drug: lisdexamfetamine;   Drug: Placebo;   Drug: fluoxetine
Outcome Measures: Clinical Global Impression-Improvement-Severe Mood Dysregulation;   Pediatric Anxiety Rating Scale (PARS);   Children's Depression Rating Scale;   ADHD-IV Rating Scale;   ADHD IV Rating Scale;   Columbia Suicide Severity Scales;   Barnes Akathisia Scale;   Children's Affective Lability Scale;   Physical Symptom Checklist;   Revised Modified Overt Aggression Scale;   Screen for Children's Affective Reactivity;   Affective Reactivity Index
6 Recruiting Treating Mothers First
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Vyvanse;   Behavioral: Behavior Parent Training
Outcome Measures: Child behavioral functioning;   Maternal behavioral functioning
7 Not yet recruiting Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
Condition: Methamphetamine Dependence
Interventions: Drug: Lisdexamfetamine;   Drug: Placebo
Outcome Measure: Percentage of participants that relapse to methamphetamine use.
8 Recruiting E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy
Condition: Planned RRSO
Interventions: Drug: LDX;   Drug: Estradiol;   Drug: Placebo
Outcome Measures: BADDS Score;   Cognitive Functioning
9 Unknown  Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Drug: Lisdexamfetamine dimesylate
Outcome Measure: ADHD rating scale IV
10 Unknown  Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?
Condition: ADHD
Intervention: Drug: lisdexamfetamine
Outcome Measures: Dyadic Parent-Child Interaction Coding System (DPICS);   Adult ADHD Rating Scale (ADHD RS);   Alabama Parenting Questionnaire (APQ);   Parenting Stress Inventory (PSI);   Parenting Locus of Control (PLC);   The Brown Attention-Deficit Disorder Scales (BAADS);   Social Skills Rating Scale (SSRS);   Disruptive Behavior Disorders Rating Scale (DBD);   Impairment Rating Scale (IRS);   Sheehan Disability Scale (SDS);   ADHD Severity Clinical Global Impressions (CGI);   Barkley's Home Situations Questionnaire (HSQ);   Adverse Events;   Vital Signs;   Abbreviated Alabama Parenting Questionnaire (brief-APQ);   ADHD Rating Scale (ADHD RS);   Parenting Stress Index (PSI);   Brown Attention Deficit Scale (BAADS);   Disruptive Behavior Disorder Rating Scale (DBD);   ADHD Severity CGI;   Barkley Home Situations Questionnaire (HSQ);   Barkley HSQ;   adverse events;   vital signs;   Brief Alabama Parenting Questionnaire APQ;   Brief APQ
11 Recruiting LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy
Conditions: Cognitive Impairments;   RRSO
Interventions: Drug: lisdexamfetamine;   Drug: Placebo
Outcome Measures: BADDS Score;   Brain Activation
12 Recruiting Examining Emotional Lability in Patients With Attention Deficit Hyperactivity Disorder (ADHD): An fMRI Study
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine;   Drug: Placebo
Outcome Measure: Emotional lability as determined by fMRI signal
13 Not yet recruiting ADHD Medication and Predictors of Treatment Outcome
Condition: Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions: Drug: methylphenidate medication;   Drug: atomoxetine medication;   Drug: lisdexamphetamine medication
Outcome Measures: change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale);   change in P-SEC (Pediatric Side Effects Checklist);   change in CGI-S (Clinical Global Impression- of Severity);   change in C-GAS (Children´s global assessment scale);   change in SNAP-IV Teacher and Parent rating scale;   change in Spence Children's Anxiety Scale (SCAS);   change in heart rate;   change in systolic blood pressure;   change in diastolic blood pressure;   change in weight z-score;   change in height z-score
14 Recruiting Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Behavioral: Academic and Organization skills;   Behavioral: Parent Training;   Behavioral: Social Skills Training;   Drug: Long-acting stimulant
Outcome Measures: Attention Deficit Hyperactivity Disorder (ADHD) symptomatology (measured via Conners' Global Index - Parent and Teacher Version);   Social skills (measured via Parent and Teacher Social Skills Rating Scale);   Academic achievement (measured via Wechsler Individual Achievement Test (WIAT));   Emotional and symptomatic functioning (measured via the Achenbach Child Behavior Check List (CBCL));   Overall functioning (measured via the Weiss Functional Impairment Scale (WFIRS));   Overall functioning (measured via the Clinical Global Impression Scale (CGI))
15 Recruiting Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Condition: Binge Eating Disorder
Interventions: Drug: Lisdexamfetamine dimesylate;   Other: Placebo
Outcome Measures: Time to Relapse of Binge Eating;   Number of Binge-Eating Days Per Week;   Clinical Global Impression-Severity of Illness (CGI-S) Scale;   Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE);   EuroQuol Questionnaire (EQ-5D-5L);   Columbia-Suicide Severity Rating Scale (C-SSRS);   Amphetamine Cessation Symptom Assessment (ACSA)
16 Recruiting Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
Conditions: Attention Deficit Hyperactivity Disorder (ADHD);   Deficient Emotional Self-Regulation (DESR)
Interventions: Drug: ADHD Medication;   Drug: Omega-3 Fatty Acids
Outcome Measures: Efficacy assessed by mean change from baseline to endpoint on the BRIEF-A Emotional Control scale;   Efficacy measured by mean change from baseline to endpoint on AISRS total score;   Efficacy measured by mean change from baseline to endpoint on CGI;   Efficacy measured by mean change from baseline to endpoint on BRIEF-A subscales;   Efficacy measured by mean change from baseline to endpoint on GAF
17 Not yet recruiting Event Rate and Effects of Stimulants in ADHD
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LDX.;   Drug: sugar pill;   Device: computer task (Go/No-Go task);   Device: EEG;   Device: pupil size measurements (by using eye tracking)
Outcome Measures: Performance data (by using computerized Go-No Go task);   psychophysiological data
18 Recruiting Efficacy of Intuniv Extended Release as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Guanfacine extended release;   Drug: Placebo
Outcome Measures: To evaluate the effect of adjunctive INTUNIV extended release treatment on executive function as assessed by the BRIEF-parent questionnaires;   To evaluate the effect of adjunctive INTUNIV extended release treatment on quality of life as assessed by the KINDL®-child and KINDL®-parent questionnaires.;   To examine the congruency of the perceived effect of treatment on EF and quality of life from the perspective of the subject, parent, and teacher.;   To evaluate the effect of adjunct therapy on ADHD symptom control as assessed by the ADHD Rating Scale (ADHD-RS-IV) and Clinical Global Impression (CGI) of Severity (CGI-S) and of Improvement (CGI-I) questionnaires.;   To compare the percentage of subjects experiencing suicidal ideation, suicidal behaviour and self-injurious behaviour without suicidal intent and incident of Serious Adverse Events in each treatment arm

These studies may lead to new treatments and are adding insight into Vyvanse etiology and treatment.

A major focus of Vyvanse research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Vyvanse

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us

privacy policy